All the Beauty M&A Deals of 2024

Here is a list of all the beauty acquisitions and investments so far in 2024:

November

More from WWD

Helen of Troy is acquiring the nail care brand for $225 million in cash and a $15 million earnout subject to performance over three years, the two companies announced Thursday. The acquisition is expected to close before the year end.

Crown Affair has closed its $9 million Series B funding round, led by True Beauty Ventures. This marks True Beauty Ventures’ fourth investment in Crown Affair, who also led the brand’s $5 million Series A fundraise in 2022.

Shiseido Long Term Investments for the Future Ventures acquired a minority stake in wellness brand Apothékary.

Dsm-Firmenich, the Swiss fragrance and flavors supplier, said it sold its remaining 1 percent stake in French natural fragrance and flavors supplier Robertet.

Scalp care brand Divi landed a minority investment from Norwest Venture Partners.

October

Two contract beauty manufacturers are joining forces, with SV Labs Corporation acquiring Sigan Industries Group Inc.

Yse Beauty, the skin care line, founded in April 2023 by author and actress Molly Sims, has landed an investment from Los Angeles-based private equity firm Willow Growth Partners, whose other beauty investments include Bubble, Kosas and hair care brands Dae and Jupiter.

Amerikas, a beauty products distributor, acquired the vegan, cruelty-free and natural skin care brand Skyn Iceland from a group of French and Swiss investors.

September

Seen, the hair care brand developed by Harvard-trained dermatologist Dr. Iris Rubin after she experienced breakouts that were traced back to her hair care products, closed a $9 million Series A funding.

Label Capital made a 5 million euro minority investment in IVB Wellness Lab, a Spanish holistic supplements brand.

Violet Grey is back under old — and new — ownership. Cassandra Grey has acquired the luxury retailer back from Coupang-owned Farfetch, with help from private equity veteran Sherif Guirgis, who is helming the company as chairman, chief executive officer and co-owner.

L’Oréal participated in a 35-million-euro funding round for French biotech company Abolis Biotechnologies in the quest to create purpose-made, sustainable ingredients produced at scale. The minority investment was made through Business Opportunities for L’Oréal Development, or BOLD, the group’s venture capital fund. The deal is part of a three-way partnership. Evonik CVC, a global specialty manufacturer that’s a long-standing partner of L’Oréal, has also taken a minority share in Abolis, while other investors include Deep Tech & Climate Fund, Clay Partners, Icos Capital and Liberset.